- Home
- CSIQ vs PHAT Comparison
CSIQ vs PHAT Comparison
Compare CSIQ & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSIQ | PHAT |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 824.4M | 894.0M |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CSIQ | PHAT |
|---|---|---|
| Price | $18.87 | $11.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $17.36 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 3.1M | 1.3M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $23.61 | $93.04 |
| Revenue Next Year | $13.90 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $9.41 | $3.92 |
| 52 Week High | $34.59 | $18.31 |
Technical Indicators
Market Signals| Indicator | CSIQ | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 60.07 | 43.75 |
| Support Level | $12.75 | $11.04 |
| Resistance Level | $20.60 | $12.83 |
| Average True Range (ATR) | 1.53 | 0.73 |
| MACD | -0.04 | -0.13 |
| Stochastic Oscillator | 68.50 | 8.04 |
Price Performance
Historical ComparisonAbout CSIQ Canadian Solar Inc. (ON)
Canadian Solar Inc is a Canadian solar technology and renewable energy company. It is a manufacturer of solar photovoltaic modules, a provider of battery energy storage solutions, and a developer of utility-scale solar power and battery energy storage projects.. It operates through two business segments CSI Solar and Recurrent Energy segment. The CSI Solar segment focused on solar modules and battery energy storage manufacturing and products. Its Recurrent segment focused on utility-scale solar power and battery energy storage project development and operation. Key revenue is generated from CSI Solar segment.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.